Skip to content

Vor Biopharma VOR Quick ratio

Quick ratio at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.8×-0.3×
Amgen logo
AmgenAMGN
+0.1×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
29.3×+13.3×
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
22.3×-6.1×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

Based on the most recent quarter.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's quick ratio?
Vor Biopharma (VOR) reported quick ratio of 31.1× in Q1 2026.
How has Vor Biopharma's quick ratio changed year-over-year?
Vor Biopharma's quick ratio increased by 703.5% year-over-year, from 3.9× to 31.1×.
What is the long-term trend for Vor Biopharma's quick ratio?
Over 5 years (2020 to 2025), Vor Biopharma's quick ratio has grown at a 30.5% compound annual growth rate (CAGR), from 4.8× to 18.2×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.